The Molecular Nature of Very Small Embryonic-Like Stem Cells in Adult Tissues

YongHwan Kim1,2,*, Jaeho Jeong1,2,*, Hyunsook Kang1,2, Jisun Lim1,2, Jinbeom Heo1,2, Janina Ratajczak3, Mariusz Z. Ratajczak3, Dong-Myung Shin1,2

1Department of Biomedical Sciences, University of Ulsan College of Medicine, Seoul, Korea, 2Department of Physiology, University of Ulsan College of Medicine, Seoul, Korea, 3Stem Cell Institute at the James Graham Brown Cancer Center, University of Louisville, KY, USA

Pluripotent stem cells (PSCs) have been considered as the most important cells in regenerative medicine as they are able to differentiate into all types of cells in the human body. PSCs have been established from several sources of embryo tissue or by reprogramming of terminally differentiated adult tissue by transduction of so-called Yamanaka factors (Oct4, Sox2, Klf4, and cMyc). Interestingly, accumulating evidence has demonstrated the residence of PSCs in adult tissue and with the ability to differentiate into multiple types of tissue-committed stem cells (TCSCs). We also recently demonstrated that a population of pluripotent Oct4+ SSEA-1+Sca-1+Lin-CD45 very small embryonic-like stem cells (VSELs) resides in the adult murine bone marrow (BM) and in other murine tissue. These very small (∼3-6 μm) cells express pluripotent markers such as Oct4, Nanog, and SSEA-1. VSELs could be specified into several tissue-residing TCSCs in response to tissue/organ injury, and thus suggesting that these cells have a physiological role in the rejuvenation of a pool of TCSCs under steady-state conditions. In this review article, we discuss the molecular nature of the rare population of VSELs which have a crucial role in regulating the pluripotency, proliferation, differentiation, and aging of these cells.

Keywords: VSEL, PGC, Genomic Imprinting, DNA Methylation, Pluripotency

Introduction

Embryonic development and later rejuvenation of adult tissue is regulated by a population of stem cells that, by undergoing self-renewal maintain their own pool and give rise to differentiated progenitors that replace cells used up during the life cycle (1). Therefore, SCs are guardians of tissue/organ integrity and regulate the life span of an adult organism.

The most important SC population, from a regenerative point of view, is pluripotent stem cells (PSCs) (2). Such cells, according to their definition, must fulfill some in vitro as well as in vivo criteria, such as i) they give rise to cells from all three germ layers, i.e. the ectoderm, mesoderm, and endoderm; ii) complete blastocyst development; and iii) form teratomas after inoculation into experimental animals (3). During embryo development, pluripotent stem cells are established from the most primitive stem cells, i.e. fertilized zygote. These cells are called totipotent — and possess the ability to give rise to both embryo and placenta. Totipotent zygotes further develop into PSCs in the inner cell mass (ICM) of blastocysts and may give rise
to all three germ layers of a developing embryo, however, they lose the ability to differentiate into placenta. The PSCs in this stage could be expanded ex vivo as embryonic stem cell (ESCs) lines (4, 5).

The pluripotency is inherited from fertilized zygote, cells from inner-cell mass in blastocysts, to epiblasts from primitive ectoderm after implantation (6). After gastrulation, almost all cells lose their pluripotency and are committed into specialized lineage. However, primordial germ cells (PGCs) derived from proximal epiblast cells, germ-line stem cells maintain their pluripotency by expressing pluripotency-specific genes, such as Oct4 and Nanog (7). The PGCs also lose their pluripotency and initiate their commitment to gametes, i.e., oocytes and sperm cells, after migration into the genital ridge. Therefore, the PSCs could be specific population detected during only the narrow developmental period of early embryogenesis. Indeed, embryonic stem cells (ESCs), epiblast-derived stem cells (EpiSCs), and embryonic germ cells (EGCs) are established from these early embryonic PSCs using specialized in-vitro cell cultures (3).

As previously mentioned, PSCs are detected only during very early embryonic development and they disappear in adulthood as they differentiate into terminally differentiated monopotent somatic or germ-line cells (2). However, several attempts have been made in the past few years to purify a population of pluripotent stem cells (PSCs) from adult tissue. Potential PSCs in adult tissue were described as i) multipotent adult progenitor cells (MAPCs) (8), ii) multipotent adult stem-cells (MASCs) (9, 10), iii) unrestricted somatic stem-cells (USSCs) (11), iv) marrow-isolated adult multilineage-inducible (MIAMI) cells (12), and v) multilineage-differentiating, stress-enduring stem (Muse) cells (13). It is conceivable that all of these cells may be closely related and some stem cell described by different investigators may be overlapped.

Our group recently isolated a population of pluripotent, very small, embryonic-like stem cells (VSELs) from adult, murine bone marrow (BM) (14), fetal livers (15), several adult-murine organs (16), and also from human cord blood (17). VSELs express many morphological, e.g., relatively large nuclei containing euchromatin, and molecular, e.g., expression of SSEA-1, Oct4, and Nanog, markers characteristic for ESCs (14). We hypothesize that VSELs are deposited during early gastrulation in developing tissues/ organs, survive into adulthood, and have an important role as a back-up population of PSCs in the turnover of tissue-committed stem cells (TCSCs). In this review article, we will discuss in detail the molecular nature of the Oct4+ VSELs.

### Very small, embryonic-like stem cells (VSELs) obtained from adult tissue

VSELs were isolated using the multiparameter fluorescence-activated cell sorter (FACS) as a population of Sca-1-LinCD45 in several other adult murine organs, e.g., brain, liver, skeletal muscles, heart, and kidney, and as a population of CD133CXCR4LinCD45 in human cord blood and peripheral blood (14, 16, 17). These very small sized (~3-6 μm) cells express pluripotent markers such as Oct4, Nanog, and SSEA-1 (mouse) or SSEA-4 (human). Morphologically, VSELs similarly to ESCs possess large nuclei containing unorganized chromatin (euchromatin) and exhibit a significantly higher nuclear/cytoplasm (N/C) ratio and a lower cytoplasmic area compared to HSCs (16).

When freshly isolated VSELs are cultured under a C2C12 myoblast feeder layer, they form spheres that correspond to embryoid bodies (EBs) from ESCs (18). The VSEL-derived spheres (VSEL-DSs) contain primitive SCs that, after replating into specific, differentiation-inducing media differentiate into cells from all three germ layers. Furthermore, we reported that VSELs are mobilized into peripheral blood during several models of organ injury and circulate there in an attempt to enrich and regenerate damaged tissue, e.g., heart infarct and stroke (19-24). This physiological mechanism undoubtedly has a more significant role in the regeneration of some small tissue and organ injuries.

### Molecular signature of VSELs residing in BM

To investigate the relationship between VSELs and the embryonic type of PSCs, e.g., ESCs, EpiSCs, PGCs, and EGCs, we used several molecular strategies to evaluate the molecular signature of VSELs. Highly purified Sca-1-LinCD45 VSELs from murine BM were evaluated for expression of i) pluripotent genes, ii) epiblast/germ line markers, and iii) expression of developmentally crucial imprinted genes (Fig. 1).

### VSELs express PSC genes

Unlike differentiated somatic cells, PSCs commonly express pluripotency core transcription factors (TFs), such as Oct4, Nanog, and Sox2. These TFs form the pluripotent core circuitry by reinforcing the expression of genes, and are involved in maintaining the PSC undifferentiated status but repress the differentiation inducing transcription (25). The significance of these core factors is experimentally demonstrated by the inducible pluripotent stem cells...
Fig. 1. Epigenetic modification of VSELs during embryogenesis and tissue regeneration. Epigenetic modifications control the differentiation potential of stem cells during embryogenesis and tissue regeneration. During the implantation of embryo, ICM-derived epiblast stem cells methylated again i) X chromosome, ii) promoters for the genes characteristic for PSCs in ICM (Rex-1 and Stella), and iii) repetitive sequences. However, at the beginning of gastrulation the proximal, epiblast-specified PGCs can reset their epigenetic profile to one that characterizes ICM-derived PSCs. Subsequently, during PGCs migration to genital ridges, the global DNA demethylation leads to erase the genomic imprints. As it is hypothesized that VSELs originate from the epiblast-derived PGCs population, they show the PGCs-like epigenetic profiles, including the partial DNA demethylation in the regulatory DNA elements of several pluripotency, germ-line genes, and genomic imprints. The epigenetic profiles of developing VSELs are retained after their deposition into adult tissue. This parental-specific reprogramming of genomic imprinting of VSELs deposited in adult tissue, e.g. BM, functions as i) a “lock-in mechanism” to prevent their unleashed proliferation and ii) a mechanism to restrict their sensitivity to Ins/Igf signaling. After exposure to tissue injury, quiescent VSELs de-repress “locked-in” genomic imprints along with progressive methylation of DNA in the Oct4 promoter. As a result of these epigenetic changes, VSELs become involved in the tissue regeneration process by differentiation into cells of all three germ layers, i.e. meso-, epto-, and endoderm.

(iPSCs) protocol in which fully differentiated somatic cells can be reprogrammed into ESC-like stem cells by transduction of the so-called Yamanaka factors (Oct4, Sox2, Klf4, and cMyc) (26, 27). We noted that murine VSELs express both the Oct4 transcript and protein (28). However, a few recent reports cast doubts regarding the true expression of this important PSCs marker in cells isolated from adult tissue, especially, as postulating the expression of several Oct4 pseudogenes can produce false-positive RT-PCR results (29, 30). Therefore, we evaluated in murine the epigenetic status for the Oct4 promoter, which are the most convincing in vitro criteria for the evaluation of putative stem cells. When the DNA methylation status of the Oct4 promoter was examined by bisulfate sequencing using the highly purified Sca-1LinCD45 VSELs, the Oct4 promoter in VSELs, similar to that in cells isolated
from ESCs-derived EBs, was hypomethylated (28% and 13.2%, respectively) (28). With the Carrier chromatin-immunoprecipitation (ChiP) assay using human hematopoietic cell-line THP-1 as the carrier (31), we found that the Oct4 promoter chromatin in murine VSEL is enriched with H3Ac, an open chromatin histone code, but was less associated with H3K9me2, a heterochromatin histone code (28). For determining the epigenetic status for the Nanog promoter, it was methylated (~50%) at the DNA level, however, quantitative ChiP data confirmed that the H3Ac/H3K9me2 ratio supports the active status of the Nanog promoter in these cells (28). Based on these results, VSEL exhibits the open chromatin structure in the promoter of the Oct4 and the Nanog in order to support the true expression of these genes. Of note, we also reported that VSELs express also several other markers of PSCs, such as SSEA-1 antigen as well as Sox2 and Klf4 transcription factors.

Expression of germ-line markers

After gastrulation, most embryonic cells lose their expression of pluripotency-specific TFs except for some of the SC population from proximal epiblasts, which are precursors for PGCs development. The PGCs derived from epiblast reset epitopogene markers to ICM-like status, resulting in re-activation of pluripotency and germ-line-related genes (6). The PGCs are epiblast-derived, alkaline phosphatase (AP)-positive, migratory-stem cells. They emerge in extraembryonic mesoderm at the base of the allantois, an appendage arising from the posterior, primitive streak around E7.25 (32). At this time, approximately 40 cells are detected. The specification of PGCs is initiated by the expression of germ-line master regulators, such as Fragilis, Blimp1, and Stella, in response to signals from extra-embryonic tissues (33). At E8.5, PGCs enter back into the primitive streak region of the embryo and begin migration through hindgut endoderm and mesentery in aorta-go-nads-mesonephros (AGM), and reach the genital ridge around E11.5 to E12.5. During this period, there is active proliferation, leading to ~25,000 PGCs at 13 dpc. After E13.0 (post-migration), PGCs i) cease proliferation, ii) change in cell morphology and cell-adhesion molecules, iii) lose cell migratory capacity, and iv) initiate gametogenesis. During migration, PGCs initiate epigenetic re-programming, such as erasure of genomic imprinting, DNA demethylation, and X chromosome reactivation and complete them after colonizing at the genital ridge. This epigenetic reprogramming could be responsible for the proper expression timing of various germ-line genes, such as Blimp1, Stella, Mvh, Dazl, and Sycep3 (7). Therefore, early emerging, migratory, and post-migratory PGCs show distinguished characteristics regarding the epigenetic status and gene expression profile.

Importantly, VSELs highly express the genes involved in the germ-line specification of the epiblast, e.g. Stella, Prdm14, Fragilis, Blimp1, Nanos3, and Dnd1. Subsequently, the expression of Stella, Blimp1, and Mvh protein was confirmed by immunostaining (34). The Stella promoter is partially demethylated regarding DNA methylation. In addition, this promoter was highly enriched with transcriptionally active histone modifications (H3Ac and H3K4me3), but was less enriched for transcriptionally repressive histone marks (H3K9me2 and H3K27me3) (34). Taken together, VSELs express specific genes and display a Stella promoter chromatin structure that is characteristic for germ-line specification. Interestingly, late migratory PGCs markers including Dppa2, Dppa4, and Mvh are highly expressed in VSELs, however, these cells do not express Sycp3, Dazl, and LINE1 genes that are highly expressed in post-migratory PGCs (34). Thus, our results in toto support the concept that VSELs deposited into murine BM show some similarities in gene expression and epigenetic signatures to epiblast-derived migratory PGCs (~E10.5-E11.5).

Presence of bivalent domain in murine VSELs

Owing to their limited number in adult tissue, it has been difficult to gain a better insight regarding the molecular nature of VSELs in detail. We recently established a cDNA library from 20 cells of FACS-sorted VSELs, hematopoietic stem cells (HSCs) or a cultured embryonic stem-cell line, ESC-D3 (35). By performing single-cell-based, genome-wide gene expression analysis (36), we found that VSELs show similar, but characteristic transcriptome compared with ESCs and HSCs (35). One gene of particular interest which is highly expressed in VSELs is Ezh2, a polycomb group protein. Ezh2 has an essential role for maintaining the bivalent domain (BD) epigenetic marker. In undifferentiated PSC, the promoter regions of some developmentally crucial transcription factors are epigenetically marked both the transcriptionally active H3K4me3 codes and the repressive histone ones such as trimethylated on lysine27 of histone3 (H3K27me3) and this epigenetic modification is called bivalent domain. The bivalent domain is detected mainly in the promoter region for the homeodomain containing development master TFs, such as Dlx, Irx, Lhx, Pou, Pax, and Six family proteins (37-39). Due to the overwhelming effect of transcription-repressive activity endowed from H3K27me3, the transcription of bivalent domain target genes is transiently re-
pressed in order to prevent the premature expression of the differentiation inducing TFs. However, in response to the development stimuli, the bivalent domain of these promoters is switched into a monovalent domain in order to determine their gene expression. By conducting differentiation and RNA interference experiments, we demonstrate that Ezh2 in VSELs has a similar role for preventing premature activation of lineage-committing transcription factors (35). Taken together, therefore, both positive (expression of Oct4-Nanog-Sox2 pluripotency circuitry) and negative (repression of differentiation inducing TFs by bivalent domain) regulatory mechanisms are indispensable in order to maintain the pluripotency of VSELs.

Epigenetic changes of imprinted genes that regulate VSELs pluripotency

Unlike ESCs, we noticed that murine Oct4 VSELs do not proliferate in vitro if cultured alone and do not grow teratomas in vivo. On the other hand, cells isolated from VSEL-Ds regain their proliferation potential, thus suggesting that VSELs are a quiescent cell population and that some mechanisms must exist to prevent their proliferation in a normal physiological condition. Similarly to VSELs, PGCs in cultures freshly isolated from embryos proliferate for a few days only and then disappear either because they differentiate or die (14). However, when PGCs are cultured over the feeder layer and with appropriate growth factors cocktails, they restore the proliferation potency and can be established into EG cells. Therefore, it is possible that two stem-cell populations could employ similar molecular mechanisms to regulate their pluripotency and to prevent unleashed cell proliferation.

The hallmark for epigenetic reprogramming during PGC development is erasure of genomic imprinting. Genomic imprinting is an epigenetic process ensuring paternal-specific, mono-allelic expression of so-called imprinted genes. Approximately 80 imprinted genes (expressed from maternal or paternal chromosomes only) have been reported in mouse genome and their proper mono-allelic expression regulates totipotency and pluripotency of the zygote and developmentally early stem cells, respectively (40). Furthermore, most imprinted genes, such as insulin-like growth factor 2 (Igf2), H19, Igf2 receptor (Igf2R), and p57KIP2 (also known as Cdkn1c), are directly involved in embryo growth and development. As the majority of imprinted genes exist as gene clusters enriched for CpG islands, their expression is coordinately regulated by the DNA methylation status on CpG-rich cis-elements known as differently methylated regions (DMRs) (41). The differential methylation status of DMRs is mediated by DNA methyltransferases (Dnmts), depending upon the parental allele origin. Depending on the developmental period of methylation, there are two types of DMRs, i.e. "primary DMRs" which are differentially methylated during gametogenesis, and "secondary DMRs" which acquire allelic specific methylation after fertilization. To date, 15 primary DMRs have been identified in mouse genome. Interestingly, most primary DMRs are maternally methylated ones and only three DMRs, i.e. Igf2-H19, Rasgrf1, and Meg3 loci, are paternally methylated (42). In addition to DNA methylation on DMR, histone modifications also contribute to the monoallelic expression of the imprinted genes.

Shortly after PGCs specification at E7.25, PGCs initiate the epigenetic reprogramming programs resulting in progressive global DNA demethylation and changes in histone modifications (43). As a result, DNA methylation marks for genomic imprinting in both parental chromosomes are erased during PGCs migration into the genital ridge and new genomic imprints are established during terminally maturation into gametes in the sex-dependent manner. The erasure of genomic imprints could be a potential mechanism used to restrict the Oct4 expressing germ-line stem cells from unleashed cell proliferation and teratoma formation. For example, while the nuclei of early migrating PGC at E8.5-9.5 can be successfully used as donors for nuclear transfer, nuclei from post-migratory PGC after E11.5 are unable to support full-term development (44).

Since VSELs exhibit a similar molecular signature to PGCs, we have hypothesized that VSELs might employ the epigenetic reprogramming of genomic imprinting to prevent them from unleashed proliferation and this mechanism may be responsible for maintaining their quiescent status in adult tissue. Indeed, VSELs freshly isolated from murine BM erase the paternally methylated imprints, e.g. Igf2-H19 and Rasgrf1 loci, however, at the same time they hypermethylate the maternally methylated ones, e.g. Igf2 receptor (Igf2R), Kcnq1-p57KIP2, and Pegl loci (28, 34). Because paternally expressed, imprinted-genes (Igf2 and Rasgrf1) enhance the embryo growth and maternally expressed genes (H19, p57KIP2, and Igf2R) inhibit cell proliferation (28, 34), the unique genomic imprinting pattern observed on murine VSELs demonstrates that the pattern of genomic imprints in these cells is favorable to the repression of cell proliferation. Accordingly, VSELs highly express growth-repressive imprinted gene transcripts, H19, p57KIP2, and Igf2R, and down-regulate growth-promoting ones, Igf2 and Rasgrf1, and which explains the quiescent
status of VSELs (28). Importantly, cells isolated from VSEL-Ds which proliferate and differentiate progressively recover all of the growth repressive patterns of genomic imprinting. These results suggest that epigenetic reprogramming of genomic imprinting should be primary mechanism for maintaining the quiescence of the most primitive pluripotent adult stem cells, e.g. Oct4+ VSELs, deposited in the adult body and protect them from premature aging and tumor formation (28). Indeed, we demonstrated that the epigenetic changes of some imprinted genes, Igf2-H19, Igf2R, and Ragyl1 loci regulate the responsiveness to the insulin factor signaling pathway in murine VSELs. It is well-known that the attenuation of the insulin/insulin-like growth factor (Ins/Igf) signaling that positively correlates with longevity (45). Thus, our experimental data using several animal model mice for longevity and Ins/Igf signaling demonstrate that the pool and regeneration potency of VSELs deposited in adult tissue gradually decrease throughout life in an Ins/Igf signaling-dependent manner and the ageing associated dysfunction of VSELs could be an important mechanism of aging (46-48). Therefore, the investigation of potential modulation of mechanisms controlling genomic imprinting in VSELs is crucial for developing more powerful strategies to unleash the regenerative potential of these cells for efficient use in the clinical setting.

To get a better molecular insight about the quiescent state of VSELs, we recently performed the genome-wide analysis of murine BM-derived VSELs. Accordingly, the attenuation of mitogenic growth-factor signaling pathways also has a crucial role in their quiescence and ageing (49). Of particular interest, VSELs down-regulate genes involved in the UV radiation response, mRNA processing, and mitogenic growth factor signaling, e.g. from Igf-1 and TRKA receptors as well as for the ERK and PI3K pathways. Using leading-edge, subset analysis and real-time, quantitative PCR assays, we observed that several genes, such as Grb2, Sos1, Shc1, Map2k1, Akt3, Elk1, Rps6ka3, Gsk3β, and Csnk2a1, which are involved in mitogenic growth-factor signaling pathways, were commonly down-regulated in VSELs. In contrast, we observed that Oct4+ VSELs up-regulates tissue-specific gene sets and a gene set encoding the complement-coagulation cascade. Thus, we are investigating the role of these putative molecular targets for regulating the quiescence and ageing of VSELs.

Conclusions

Several attempts have been made in the past few years to purify a population of PSCs from adult tissue. The very primitive VSELs in adult tissue could function as a precursor for monopotent TCSCs. Pluripotency of murine VSELs is already supported by their i) ability in vitro to differentiate in co-culture systems into three germ lineages, ii) the presence of primitive, unorganized euchromatin in nuclei, iii) “true expression” of Oct4 and Nanog supported by demonstration of the hypomethylated promoter status and its association with acetylated histones, and iv) the presence of bivalent domains on homeodomain-containing, developmental transcription factors. However, these cells do not grow teratomas and are ineffective in blastocyst complementation assay due to modulation of methylation on regulatory sequences in developmentally important, imprinted genes, similarly seen in PGCs, to prevent them from unleashed cell proliferation and teratoma formation. Furthermore, VSELs could be specified into several tissue residing TCSCs, e.g. MSCs, HSCs, and cardiac stem cells, in response to tissue/organ injury. Taken together, it is very likely that these cells have a physiological role in the rejuvenation of a pool of TCSCs under steady state conditions. VSELs developmentally originate from epiblast-derived, migrating PGCs and they could be deposited in adult organs early in the development as a reserve pool of primitive stem cells for tissue repair and regeneration. Therefore, VSELs isolated from adult tissue are an alternative and not ethically controversial source of stem cells for regenerative medicine. To successfully use VSELs in the realm of regenerative medicine, it is very important to establish experimental protocols for the reprogramming of growth-repressive, genomic imprinting status in VSELs into a somatic pattern in order to unleash their regenerative potential.

Acknowledgments

This work was supported by a grant from the Asian Institute for Life Sciences, Seoul, Korea (2014-528) and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2012R1 A1A1004438) that were awarded to DMS.

Potential conflict of interest

The authors have no conflicting financial interest.

References

1. Ratajczak MZ, Machalinski B, Wojakowski W, Ratajczak J, Kucia M. A hypothesis for an embryonic origin of pluripotent Oct-4(+) stem cells in adult bone marrow and other
tissues. Leukemia 2007;21:860-867
2. Ratajczak MZ, Liu R, Ratajczak J, Kucia M, Shin DM. The role of pluripotent embryonic-like stem cells residing in adult tissues in regeneration and longevity. Differentiation 2011;81:153-161
3. Niwa H. How is pluripotency determined and maintained? Development 2007;134:635-646
4. Evans MJ, Kaufman MH. Establishment in culture of pluripotent cells from mouse embryos. Nature 1981;292:154-156
5. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-1147
6. Hayashi K, Surani MA. Resetting the epigenome beyond pluripotency in the germline. Cell Stem Cell 2009;4:493-498
7. Surani MA, Hayashi K, Hajkova P. Genetic and epigenetic regulators of pluripotency. Cell 2007;128:747-762
8. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-49
9. Pochampally RR, Smith JR, Ylostalo J, Prockop DJ. Serum factors from bone marrow stromal cells (hMSCs) selects for a subpopulation of early progenitor cells with enhanced expression of OCT-4 and other embryonic genes. Blood 2004;103:1647-1652
10. Beltrami AP, Cesselli D, Bergamin N, Marcon P, Rigo S, Puppato E, D’Aurizio F, Schneider C, Beltrami CA. Multipotent cells can be generated in vitro from several adult human organs (heart, liver, and bone marrow). Blood 2007;10:3438-3446
11. Kögl G, Sensken S, Airey JA, Trapp T, Mäuslein M, Feldhahn N, Liedtke S, Sorg RV, Fischer J, Rosenbaum C, Feldhahn N, Liedtke S, Sorg RV, Fischer J, Rosenbaum C, Greschat S, Knipper A, Bend J, Degistirici O, Gao J, Caplan AI, Colletti EJ, Almeida-Porada G, Müller HW, Buszman P, Ocha A, Ratajczak J, Ratajczak MZ. Mobilization of bone marrow-derived Oct-4+ SSEA-4+ very small embryonic-like stem cells in patients with acute myeloid leukemia. Leukemia 2008;22:153-161
12. D’Ippolito G, Diabira S, Howard GA, Menei P, Roos BA, Schiller PC. Marrow-isolated adult multiline inducible (MAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004;17:2971-2981
13. Kuroda Y, Kitada M, Walao S, Nishikawa K, Tanimura Y, Makinoshima H, Guda M, Akashi H, Inutsuka S, Niwa A, Shigemoto T, Nabeshima Y, Nakahata T, Nabeshima Y, Fujiyoshi Y, Dezawa M. Unique multipotent cells in adult human mesenchymal cell populations. Proc Natl Acad Sci U S A 2010;107:8639-8643
14. Kucia M, Reca R, Campbell FR, Zuba-Surma E, Majka M, Ratajczak J, Ratajczak MZ. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia 2006;20:857-869
15. Zuba-Surma EK, Kucia M, Rui L, Shin DM, Wojakowski W, Ratajczak J, Ratajczak MZ. Fetal liver very small embryonic/epiblast like stem cells follow developmental migratory pathway of hematopoietic stem cells. Ann N Y Acad Sci 2009;1176:205-218
16. Zuba-Surma EK, Kucia M, Wu W, Klich I, Lillard JW Jr, Ratajczak J, Ratajczak MZ. Very small embryonic-like stem cells are present in adult murine organs: ImageStream-based morphological analysis and distribution studies. Cytometry A 2008;73A:1116-1127
17. Kucia M, Halasa M, Wisoczynski M, Baskiewicz-Masiuk M, Holdenawer S, Zuba-Surma E, Czajka R, Wojakowski W, Machalinski B, Ratajczak MZ. Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human cord blood: preliminary report. Leukemia 2007;21:297-303
18. Kucia M, Wisoczynski M, Ratajczak J, Ratajczak MZ. Identification of very small embryonic-like (VSEL) stem cells in bone marrow. Cell Tissue Res 2008;331:125-134
19. Kucia MJ, Wisoczynski M, Wu W, Zuba-Surma EK, Ratajczak J, Ratajczak MZ. Evidence that very small embryonic-like stem cells are mobilized into peripheral blood. Stem Cells 2008;26:2083-2092
20. Wojakowski W, Tendera M, Kucia M, Zuba-Surma EK, Paczkowska E, Ciosek J, Halasa M, Krol M, Kazmiierski M, Buszman P, Ocha A, Ratajczak J, Machalinski B, Ratajczak MZ. Mobilization of bone marrow-derived Oct-4+ SSEA-4+ very small embryonic-like stem cells in patients with acute myocardial infarction. J Am Coll Cardiol 2009;53:1-9
21. Paczkowska E, Kucia M, Kozierska D, Halasa M, Safranow K, Masiuk M, Karbicka A, Nowik M, Nowacki P, Ratajczak MZ, Machalinski B. Clinical evidence that very small embryonic-like stem cells are mobilized into peripheral blood in patients after stroke. Stroke 2009;40:1237-1244
22. Druka J, Paczkowska E, Kucia M, Mityuska E, Krajewski A, Machaliński B, Madeja Z, Ratajczak MZ. Stem cells, including a population of very small embryonic-like stem cells, are mobilized into peripheral blood in patients after skin burn injury. Stem Cell Rev 2012;8:184-194
23. Marlicz W, Zuba-Surma E, Kucia M, Blogowski W, Starzynska T, Ratajczak MZ. Various types of stem cells, including a population of very small embryonic-like stem cells, are mobilized into peripheral blood in patients with Crohn’s disease. Inflamm Bowel Dis 2012;18:1711-1722
24. Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, Berry JE, McGee S, Lee E, Sun H, Wang J, Jin T, Zhang H, Dai J, Krebsbach PH, Keller ET, Pienta KJ, Taichman RS. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun 2013;4:1795
25. Kim J, Chu J, Shen X, Wang J, Orkin SH. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008;132:1049-1061
26. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures identified in adult bone marrow. Leukemia 2006;20:857-869
by defined factors. Cell 2006;126:663-676

27. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007;448:318-324

28. Shin DM, Zuba-Surma EK, Wu W, Ratajczak J, Wysoczynski M, Ratajczak MZ, Kucia M. Novel epigenetic mechanisms that control pluri potency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells. Leukemia 2009;23:2042-2051

29. Liedtke S, Enczmann J, Waclawczyk S, Wernet P, Kögl G. Oct4 and its pseudogenes confuse stem cell research. Cell Stem Cell 2007;1:364-386

30. Lengner CJ, Camargo FD, Hochedlinger K, Welstead GG, Zaidi S, Gokhale S, Scholer HR, Tomilin A, Jaenisch R. Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell 2007;1:403-415

31. O'Neill LP, VerMilyea MD, Turner BM. Epigenetic characterization of the early embryo with a chromatin immunoprecipitation protocol applicable to small cell populations. Nat Genet 2006;38:835-841

32. Wylie C. Germ cells. Cell 1999;96:165-174

33. Wernig M, Meissner A, Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007;448:318-324

34. Shin DM, Zuba-Surma EK, Wu W, Ratajczak J, Wysoczynski M, Ratajczak MZ, Kucia M. Novel epigenetic mechanisms that control pluri potency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells. Leukemia 2009;23:2042-2051

35. Seki Y, Yamaji M, Yabuta Y, Sano M, Shigeta M, Matsui Y, Saka Y, Tachibana M, Shinkai Y, Saitou M. Cellular dynamics associated with the genome-wide epigenetic reprogramming in migrating primordial germ cells in mice. Development 2007;134:2627-2638

36. Yamazaki Y, Mann MR, Lee SS, Marh J, McCarey JR, Yanagimachi R, Bartolomei MS. Reprogramming of primordial germ cells begins before migration into the genital ridge, making these cells inadequate donors for reproductive cloning. Proc Natl Acad Sci U S A 2003;100:12207-12212

37. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, Levine SS, Wernig M, Tajonar A, Ray MK, Bell GW, Otte AP, Vidal M, Gifford DK, Young RA, Jaenisch R. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006;441:349-353

38. Stock JK, Giadrossi S, Casanova M, Brookes E, Vidal M, Koseki H, Brockdorff N, Fisher AG, Pombo A. Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells. Nat Cell Biol 2007;9:1428-1435

39. Reik W, Walter J. Genomic imprinting: parental influence on the genome. Nat Rev Genet 2001;2:21-32

40. Delaval K, Feil R. Epigenetic regulation of mammalian genomic imprinting. Curr Opin Genet Dev 2004;14:188-195

41. Kobayashi H, Suda C, Abe T, Kohara Y, Ikemura T, Sasaki H. Bisulfite sequencing and dinucleotide content analysis of 15 imprinted mouse differentially methylated regions (DMRs): paternally methylated DMRs contain less CpGs than maternally methylated DMRs. Cyto genet Res Genomes 2006;113:130-137

42. Kurimoto K, Yabuta Y, Ohnata Y, Saitou M. Global sin-gulation protocol applicable to small cell populations. Nat Protoc 2007;2:739-752

43. Delaval K, Feil R. Epigenetic regulation of mammalian genomic imprinting. Curr Opin Genet Dev 2004;14:188-195

44. Yamazaki Y, Mann MR, Lee SS, Marh J, McCarey JR, Yanagimachi R, Bartolomei MS. Reprogramming of primordial germ cells begins before migration into the genital ridge, making these cells inadequate donors for reproductive cloning. Proc Natl Acad Sci U S A 2003;100:12207-12212

45. Russell SJ, Kahn CR. Endocrine regulation of ageing. Nat Rev Mol Cell Biol 2007;8:681-691

46. Ratajczak J, Shin DM, Wan W, Liu R, Masternak MM, Piotrowska K, Wiszniewska B, Kucia M, Bartke A, Ratajczak MZ. Higher number of stem cells in the bone marrow of circulating low Igf-1 level Laron dwarf mice–novel view on Igf-I, stem cells and aging. Leukemia 2011;25:729-733

47. Kucia M, Shin DM, Liu R, Ratajczak J, Bryndza E, Masternak MM, Bartke A, Ratajczak MZ. Reduced number of VSELs in the bone marrow of growth hormone transgenic mice indicates that chronically elevated Igf1 level accelerates age-dependent exhaustion of pluripotent stem cell pool: a novel view on aging. Leukemia 2011;25:1370-1374

48. Mierzejewska K, Heo J, Kang JW, Kang H, Ratajczak J, Ratajczak MZ, Kucia M, Shin DM. Genome-wide analysis of murine bone marrow-derived very small embryonic-like stem cells reveals that mitogenic growth factor signaling pathways play a crucial role in the quiescence and ageing of these cells. Int J Mol Med 2013;32:281-290